To decrease the heterogeneity between the trials, a third analysis was made by including HR for RFS (excluding non-breast cancer related deaths before recurrence) of estrogen receptor-positive patients for ATAC trial and HR for EFS of all patients for the rest of the trials. Here, ESR1 is linked to breast carcinoma.